常规处方非甾体抗炎药与COVID-19死亡风险:OpenSAFELY两项队列分析
基于OpenSAFELY平台的两项队列研究,利用英格兰常规临床数据与死亡数据,评估2020年3月1日前4个月内当前处方NSAIDs与COVID-19相关死亡的关系。研究1一般人群中当前使用NSAIDs与COVID-19死亡风险无差异(HR 0.96,95%CI 0.80-1.14);研究2类风湿关节炎/骨关节炎人群中当前使用NSAIDs与较低风险相关(HR 0.78,95%CI 0.64-0.94)。结论认为常规处方NSAIDs未显示对COVID-19死亡的有害效应。
要点
- 一般人群中当前处方NSAIDs与COVID-19死亡风险无显著差异(HR 0.96,95%CI 0.80-1.14)。
- 类风湿关节炎/骨关节炎人群中当前处方NSAIDs与较低COVID-19死亡风险相关(HR 0.78,95%CI 0.64-0.94)。
- 常规治疗性使用NSAIDs的决策无需因COVID-19风险而改变。
核心结论
- 常规处方NSAIDs未显示对COVID-19相关死亡的有害效应,COVID-19风险不需影响NSAIDs常规治疗决策。
研究设计与样本
- 基于OpenSAFELY平台的两项队列研究,数据为2020年3月1日至6月14日英格兰常规临床数据链接死亡数据。
- 研究1从一般人群识别近3年有NSAID处方者,研究2识别类风湿关节炎/骨关节炎患者;暴露定义为2020年3月1日前4个月内当前NSAID处方。
- 采用Cox回归估计当前处方NSAIDs者相比非当前处方者的COVID-19相关死亡HR,校正年龄、性别、合并症、其他药物和地理区域。
主要发现
- 研究2多变量校正模型显示当前使用NSAID相比非使用与较低COVID-19相关死亡风险相关(HR 0.78,95%CI 0.64-0.94)。
临床怎么用
- 常规治疗性使用NSAIDs的决策无需因COVID-19风险而改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the association between routinely prescribed non-steroidal anti-inflammatory drugs (NSAIDs) and deaths from COVID-19 using OpenSAFELY, a secure analytical platform. METHODS: We conducted two cohort studies from 1 March to 14 June 2020. Working on behalf of National Health Service England, we used routine clinical data in England linked to death data. In study 1, we identified people with an NSAID prescription in the last 3 years from the general population. In study 2, we identified people with rheumatoid arthritis/osteoarthritis. We defined exposure as current NSAID prescription within the 4 months before 1 March 2020. We used Cox regression to estimate HRs for COVID-19 related death in people currently prescribed NSAIDs, compared with those not currently prescribed NSAIDs, accounting for age, sex, comorbidities, other medications and geographical region. RESULTS: In study 1, we included 536 423 current NSAID users and 1 927 284 non-users in the general population. We observed no evidence of difference in risk of COVID-19 related death associated with current use (HR 0.96, 95% CI 0.80 to 1.14) in the multivariable-adjusted model. In study 2, we included 1 708 781 people with rheumatoid arthritis/osteoarthritis, of whom 175 495 (10%) were current NSAID users. In the multivariable-adjusted model, we observed a lower risk of COVID-19 related death (HR 0.78, 95% CI 0.64 to 0.94) associated with current use of NSAID versus non-use. CONCLUSIONS: We found no evidence of a harmful effect of routinely prescribed NSAIDs on COVID-19 related deaths. Risks of COVID-19 do not need to influence decisions about the routine therapeutic use of NSAIDs.
引用
- Wong AY, MacKenna B, Morton CE, et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021. PMID: 33478953. doi:10.1136/annrheumdis-2020-219517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。